Hannah Vaughan
Physician Assistant · Enid, OKNPI 1043724420
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 435 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 435 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Insmed, Inc.$1K
- Sanofi$775
- Boehringer Ingelheim$690
- Mylan Specialty L.p.$474
- plus $2K from 14 others
What the payments were for
- Food & beverage$7,65597%
- Education$2383%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 68 | $1,792 |
| GSK | 106 | $1,421 |
| Insmed, Inc. | 53 | $1,031 |
| Sanofi | 37 | $775 |
| Boehringer Ingelheim | 39 | $690 |
| Mylan Specialty L.p. | 38 | $474 |
| Regeneron Healthcare Solutions, Inc. | 26 | $414 |
| Novartis | 14 | $325 |
| Actelion Pharmaceuticals US, Inc. | 8 | $195 |
| Viatris Specialty LLC | 15 | $165 |
| Amgen | 8 | $147 |
| Grifols USA, LLC | 5 | $112 |
| United Therapeutics Corporation | 3 | $67 |
| Genentech USA, Inc. | 3 | $62 |
| Sanofi-aventis U.S. LLC | 1 | $62 |
| Baxter Healthcare | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Verona Pharma, Inc. | 2 | $31 |
| Electromed, Inc. | 3 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,893 in reported general payments places this provider in the 95th percentile of 1,491 physician assistant providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 703 | $504,639 |
| OfevNintedanib Esylate | 17 | $222,178 |
| XolairOmalizumab | 26 | $122,017 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 159 | $104,186 |
| Dupixent PenDupilumab | 26 | $96,286 |
| Dupixent SyringeDupilumab | 11 | $40,494 |
| Breo ElliptaFluticasone/Vilanterol | 76 | $34,987 |
| Spiriva RespimatTiotropium Bromide | 51 | $30,119 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 46 | $23,718 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $14,695 |
| Advair HfaFluticasone Propion/Salmeterol | 35 | $13,433 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $11,761 |
| DuleraMometasone/Formoterol | 31 | $11,109 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 348 | $8,421 |
| EliquisApixaban | 14 | $8,203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,421 | $568,883848 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $690 | $266,99184 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,792 | $115,947196 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,491 physician assistant providers in Oklahoma.
Other physician assistant in Enid
- Eric CampbellEdmond$246K
- Jennifer SmithOklahoma City$134K
- Christy NiehuesMustang$28K
- Matthew PattonTulsa$24K
- Sarah HawkOklahoma City$23K
- Gavin ChristieEdmond$19K
- Michelle GreenTulsa$18K
- Muge ParkTulsa$17K
- Rose RamirezTulsa$15K
- Melissa RohrerTulsa$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.